BCN Peptides
About BCN Peptides
Certifications
Categories
-
Country/Region:Spain
-
On CPHI since:2015
-
Certificates:4
-
Employees:50 - 99
CPHI & PMEC China 2026
Shanghai New International Expo Center
CPHI Milan 2026
Fiera Milano, Italy
Products from BCN Peptides (5)
-
Product GENERIC PEPTIDES
BCNpeptides manufactures a wide range of Generic Peptides under strict GMP conditions at commercial scale for pharmaceutical and veterinary applications.
Our Generic Peptides are supported by regulatory filing in their respective markets and BCN Peptides will fully support you with the req... -
Product PRODUCT LIST
ACTH, Abaloparatide, Afametanotide, Alarelin, Angiotensin I/II (1-7), Angiotensin II, Arginine Vasopressin, Atosiban, Buserelin, Carbetocin, Carperitide, Desmopressin, Elcatonin, Eledoisin, Etelcalcetide, Fertirelin, GHRP-6, GLP-1 (7-37), Ganirelix, Glucagon, Gonadorelin, Goserelin, Icatibant, Lanreotide, ... -
Product COSMETIC PEPTIDES
We are pioneers in the production of cosmetic peptides with more than 25 years of experience in this field. As such important ingredients are used as anti-wrinkle, firming or pigmentation reduction, we ensure the highest quality standards for GMP cosmetic peptide production. -
Product CUSTOMS SYNTHESIS OF PEPTIDES
BCN Peptides is an industrial manufacturer with the capacity to produce from milligram to multi-kg batches of pharmaceutical peptides.
We are experts in the synthesis of long and complex New Chemical Entities.BCN Peptides ensures the highest qualities and shortest times thanks to our experience ... -
Product NEOANTIGEN PEPTIDES
Our Peptide-based Personalised Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology to meet the unique requirements of neoantigens production. A dedicated and experienced team of chemists and doctors ensures full control of the processes.
The implementati...
BCN Peptides Resources (1)
-
News BCN Peptides Plant Expansion: Quadrupling Production Capacity by October 2024
We are thrilled to announce the expansion of our state-of-the-art plant in October 2024. This newly accredited facility marks a significant milestone in our mission to revolutionize peptide production.



